On August 22, Arcutis Biotherapeutics, Inc announced Arcutis Cares, a patient assistance program (PAP) for financially qualified uninsured and underinsured patients. Arcutis Cares is the first ever patient assistance program (PAP) for a topical psoriasis product, and it is now open for enrollment. Those who are eligible might be able to receive ZORYVE (roflumilast) cream 0.3% at no cost.
UCB’s BIMZELX® (bimekizumab-bkzx) has been approved by the FDA, representing a major milestone in the treatment of adults with moderate to severe plaque psoriasis. Read more about this groundbreaking development.
Boehringer Ingelheim announced earlier this month that Cyltezo® (adalimumab-adbm), a U.S. Food and Drug Administration (FDA)-approved Interchangeable biosimilar to Humira® (adalimumab), is now commercially available in the United States.
Sandoz announced that Hyrimoz® (adalimumab-adaz) injection is now available in the United States starting July 1.
